{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:01:21Z","timestamp":1784646081359,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13295-6","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:07:02Z","timestamp":1779725222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond traditional tetracyclines: a real-world evaluation of effectiveness and safety of omadacycline therapy for complex bacterial infections"],"prefix":"10.1186","volume":"26","author":[{"given":"Mohammed","family":"Al Musawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"El Ghali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Morrisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Saeedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle C.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Zeuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana J.","family":"Holger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Tupayachi-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Veve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn A.","family":"Eubank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Campion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"13295_CR1","unstructured":"CDC. 2024. Antimicrobial resistance threats in the United States, 2021\u20132022. Antimicrobial Resistance. https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/update-2022.html. Retrieved 3 January 2025."},{"key":"13295_CR2","unstructured":"O\u2019Neill J. Review on antimicrobial resistance. Tackling Drug-Resistant Infections Globally. 2016."},{"key":"13295_CR3","unstructured":"The US, Food, Drug Administration. FDA\u2019s role in antimicrobial resistance (AMR) preparedness and response, and information about AMR. FDA; 2024."},{"key":"13295_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/cid\/ciz394","volume":"69","author":"JC Gallagher","year":"2019","unstructured":"Gallagher JC. Omadacycline: A Modernized Tetracycline. Clin Infect Dis. 2019;69:S1\u20135.","journal-title":"Clin Infect Dis"},{"key":"13295_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jgar.2021.09.011","volume":"27","author":"MA Pfaller","year":"2021","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019. J Global Antimicrob Resist. 2021;27:337\u201351.","journal-title":"J Global Antimicrob Resist"},{"key":"13295_CR6","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/cid\/ciz395","volume":"69","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Steenbergen J, Zhanel GG. Microbiology and Preclinical Review of Omadacycline. Clin Infect Dis. 2019;69:S6\u201315.","journal-title":"Clin Infect Dis"},{"key":"13295_CR7","doi-asserted-by":"publisher","first-page":"e00047","DOI":"10.1128\/AAC.00047-18","volume":"62","author":"L Stapert","year":"2018","unstructured":"Stapert L, Wolfe C, Shinabarger D, Marra A, Pillar C. Vitro Activities of Omadacycline and Comparators against Anaerobic Bacteria. Antimicrob Agents Chemother. 2018;62:e00047\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"13295_CR8","unstructured":"Omadacycline [package insert]. Boston, MA: Paratek Pharmaceuticals Inc.; 2018. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf."},{"key":"13295_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19:1080\u201390.","journal-title":"Lancet Infect Dis"},{"key":"13295_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. N Engl J Med. 2019;380:528\u201338.","journal-title":"N Engl J Med"},{"key":"13295_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Omadacycline for Community-Acquired Bacterial Pneumonia. N Engl J Med. 2019;380:517\u201327.","journal-title":"N Engl J Med"},{"key":"13295_CR12","unstructured":"CLSI M100-ED34:2024 Performance standards for antimicrobial susceptibility testing, 34th Edition. https:\/\/em100.edaptivedocs.net\/GetDoc.aspx?doc=CLSI%20M100%20ED34:2024&scope=user. Retrieved 8 August 2024."},{"key":"13295_CR13","unstructured":"Research C for DE and 2024. Antibacterial susceptibility test interpretive criteria. FDA."},{"key":"13295_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"13295_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"13295_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818\u201329.","journal-title":"Crit Care Med"},{"key":"13295_CR17","doi-asserted-by":"publisher","first-page":"e00824","DOI":"10.1128\/aac.00824-23","volume":"67","author":"A El Ghali","year":"2023","unstructured":"El Ghali A, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz MG, Vemula R, Wadle C, Philley JV, Mejia-Chew C, Hamad Y, Stevens RW, Zeuli JD, Webb AJ, Fiske CT, Simonyan A, Cimino CL, Mammadova M, Umana VE, Hasbun R, Butt S, Molina KC, Thomas M, Kaip EA, Bouchard J, Gore TW, Howard C, Cabanilla MG, Holger DJ, Frens JJ, Barger M, Ong A, Cohen KA, Rybak MJ. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. Antimicrob Agents Chemother. 2023;67:e00824\u201323.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13295-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13295-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:03:22Z","timestamp":1784642602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13295-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13295"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13295-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study utilized de-identified patient data and involved no direct interaction with study participants. The requirement for informed consent was waived by the Institutional Review Board due to the nature of the study. Ethical approval was obtained from the Institutional Review Board at Wayne State University (090219M1X, protocol number 1908002459) as well as from the review boards of all participating institutions. Clinical trial number: not applicable. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MJR received funding from Paratek Pharmaceuticals Inc. as an unrestricted investigator-initiated study.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1374"}}